.

Make Better Decisions

  • Identify first generic entrants
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Colorcon
Dow
Cantor Fitzgerald
UBS
Merck
Chinese Patent Office
Citi
Deloitte
US Department of Justice
Argus Health

Generated: September 23, 2017

DrugPatentWatch Database Preview

Msd Merck Co Company Profile

« Back to Dashboard

What is the competitive landscape for MSD MERCK CO, and when can generic versions of MSD MERCK CO drugs launch?

MSD MERCK CO has one approved drug.

There are two US patents protecting MSD MERCK CO drugs on MSD MERCK CO drugs in the past three years.

There are eighty-five patent family members on MSD MERCK CO drugs in forty-four countries.

Summary for Applicant: Msd Merck Co

Patents:2
Tradenames:1
Ingredients:1
NDAs:1
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Msd Merck Co
EMEND
aprepitant
FOR SUSPENSION;ORAL207865-001Dec 17, 2015RXYesYes► Subscribe► SubscribeYY ► Subscribe
Msd Merck Co
EMEND
aprepitant
FOR SUSPENSION;ORAL207865-001Dec 17, 2015RXYesYes► Subscribe► SubscribeY ► Subscribe
Msd Merck Co
EMEND
aprepitant
FOR SUSPENSION;ORAL207865-001Dec 17, 2015RXYesYes► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for MSD MERCK CO drugs

Drugname Dosage Strength Tradename Submissiondate
aprepitant
for Oral Suspension125 mg/Kit
EMEND
11/23/2016
fosaprepitant dimeglumine
Injection115 mg/vial
EMEND
1/25/2012
fosaprepitant dimeglumine
Injection150 mg/vial
EMEND
1/25/2012
aprepitant
Capsule40 mg, 80 mg and 125 mg
EMEND
11/3/2008

Non-Orange Book Patents for Msd Merck Co

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,229,010 Polymorphic form of a tachykinin receptor antagonist► Subscribe
6,583,142 Polymorphic form of a tachykinin receptor antagonist► Subscribe
6,432,953 Polymorphic form of a tachykinin receptor antagonist► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Msd Merck Co Drugs

Country Document Number Estimated Expiration
European Patent Office0994867► Subscribe
Japan4532114► Subscribe
Germany60227556► Subscribe
South Africa200404012► Subscribe
Slovenia1455756► Subscribe
Estonia9900603► Subscribe
Austria372991► Subscribe
Indonesia23191► Subscribe
Japan2005516003► Subscribe
CroatiaP980370► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Msd Merck Co Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C/GB04/011United Kingdom► SubscribePRODUCT NAME: APREPITANT, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT; REGISTERED: UK EU/1/03/262/001 20031113; UK EU/1/03/262/002 20031113; UK EU/1/03/262/003 20031113; UK EU/1/03/262/004 20031113; UK EU/1/03/262/005 20031113; UK EU/1/03/262/006 20031113
C0019France► SubscribePRODUCT NAME: FOSAPREPITANT DIMEGLUMINE; REGISTRATION NO/DATE: EU/1/07/437/001 20080111
C/GB08/021United Kingdom► SubscribePRODUCT NAME: FOSAPREPITANT AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, IN PARTICULAR THE BIS(N-METHYL-D-GLUCAMINE)SALT; REGISTERED: UK EU/1/07/437/001 20080111; UK EU/1/07/437/002 20080111
2004002Lithuania► SubscribePRODCUT NAME: 5-[[(2R,3S)-2-[(1R)-1-[3,5-BIS(TRIFLUORMETIL)FENIL]ETOKSI]-3-(4-FLUORFENIL)-4-MORFOLINIL]METIL]-1,2-DIHIDRO-3H-1,2,4-TRIAZOL-3-ONAS (APREPITANTAS); REGISTRATION NO./DATE: EU/1/03/262/001-006/20031111
C0010France► SubscribePRODUCT NAME: APREPITANT; REGISTRATION NO/DATE: EU/1/03/262/001 20031111
2004Austria► SubscribePRODUCT NAME: APREPITANT, GEGEBENENFALLS IN FORM EINES PHARMAZEUTISCH ANNEMBAREN SALZES; REGISTRATION NO/DATE: EU/1/03/262/001 - EU/1/03/262/006 20031111
2004002,C0734381Lithuania► SubscribePRODUCT NAME: 5-(((2R,3S)-2-((1R)-1-(3,5-BIS(TRIFLUORMETIL)FENIL)ETOKSI)-3-(4-FLUORFENIL)-4-MORFOLINIL)METIL)-1,2-DIHIDRO-3H-1,2,4-TRIAZOL-3-ONAS (APREPITANTAS); REGISTRATION NO/DATE: EU/1/03/262/001, 2003 11 11, EU/1/03/262/002, 2003 11 11, EU/1/03/262/003, 2003 11 11, EU/1/03/262/004, 2003 11 11, EU/1/03/262/005, 2003 11 11, EU/1/03/262/006 20031111
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Moodys
US Department of Justice
Covington
Harvard Business School
Chinese Patent Office
Farmers Insurance
Novartis
US Army
Federal Trade Commission
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot